Número 3 - EII al día

Enfermedades asociadassity and unbalanced bone metabolism in patients with inflammatory boweldisease. Inflamm Bowel Dis 1998; 4:268-75.20. Boot AM, Bouquet J, Krenning EP, de Munick Keizer-Schrama SMPF. Bonemineral density and nutritional status in children with chronic inflammatorybowel disease. Gut 1998; 42; 188-94.21. Gokhale R, Favous MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bonemineral density and nutritional status in children with chronic inflammatorybowel disease. Gastroenterology 1998; 114; 902-11.22. Motley RJ, Clements D, Evans WD,Crawley EO, Evans C, Rhodes J, et al.A four year longitudinal study of bone loss in patients with inflammatorybowel disease. Bone Miner 1993 1993; 23: 95-104.23. Ghost S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density inCrohn´s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology,1994: 107: 1031-9.24. Jahnsen J, Falch JA, Asdliand E, Mowinckel P. Bone mineral density is reducedin patients with Crohn´s disease but not in ulcerative colitis: a populationbased study. Gut 1997; 40: 313-925. Ulivieri FM, Liscindriano D, Ranzi T,Taioli E, Cermesoni L, Piodi LP, et al.Bone mineral density and body composition in patients with ulcerativecolitis : Am J Gastroenterol 2000 ; 95 : 1491-4.26. Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, et al. Decreased trabecularbone mineral density in newly diagnosed inflammatory bowel diseasepatients in Korea. J Gastroenterol Hepatol 2000;15:512-8.27. Roux C, Abitbol C, Chaussade S, Kolta S, Guillemant S, Dougados M, etal. Bone loss in patients with inflammatory disease ; a prospective study.Osteoporos int 1995:5:156-60.28. Dinca M, Fries W, Luisetto G, Peccolo F,Bottega F, Leone L, et al. Evolutionof osteopenia in inflammatory bowel disease. Am J Gastroenterol1999; 94:1292.-7.29. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G.Altered bone metabolism in inflammatory bowel disease: there is a differencebetween Crohn’s disease and ulcerative colitis. J Intern Med 2000;247:63-70.30. Robinson RJ, al-Azzawi, F, Iqbal SJ, Kryswchi T, Almond L, Abrams K, etal. Osteoporosis and determinants of bone density in patients with Crohn’sdisease. Dig Dis Sci 1998; 43:2500-6.31. Schoon EJ, van Nunen AB, Wouters, RS, Stockbrügger RW, Russel MG.Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutchpopulation-based cohort. Scand J Gastroenterol 2000; 35:43-7.32. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are themajor predictive factors forbone mineral density in Crohn’s disease: a casecontrolcross-sectional study of 113 patients. Am J Gastroenterol 1999;94:824-8.33. Dresner-Pollak, R, Karmeli F, Eliakim R, Ackerman Z,Rachmilewitz D. Increasedurinary N-telopeptide cross-linked type 1 collagen predicts boneloss in patients with inflammatory bowel disease. Am J Gastroenterol2000; 95:699-704.34. Abitbol V, Roux C, Guillemant S, Valleur P,Hautefeuille P, Dougados M, et,al. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatorybowel disease. Br J Surg 1997; 84:1551-4.35. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, CouturierD et al. Metabolic bone assessment in patients with inflammatorybowel disease. Gastroenterology 1995; 108:417-22.36. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A, et al. Calcanealultrasound bone densitometry in inflammatory bowel disease—acomparison withdouble x-ray densitometry of the lumbar spine. Am J Gastroenterol1998; 93:2339-44.37. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral contentin patients with Crohn’s disease. A longitudinal study in patients withbowel resections. Scand J Gastroenterol 1997; 32:226-32.38. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K,et al. Bone mineraldensity inpatients with Crohn’s disease during long-term treatmentwith azathioprine. J Intern Med 1998; 243:123-6.39. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fracturesin pediatric patients with Crohn’s disease. Gastroenterology 1997;112:1710-3.40. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture riskis increased in Crohn’s disease, but not in ulcerative colitis. Gut 2000;46:176-81.41. Vestergaard, P, Mosekilde, L. Fracture risk in patients with celiac disease,Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of16,416 patients in Denmark. Am J Epidemiol 2002; 156:1-10.42. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence offracture among patients with inflammatory bowel disease. A populationbasedcohort study. Ann Intern Med 2000; 133:795-9.43. Loftus EV Jr, Crowson CS, Sandborn WJ,Tremaine WJ, O´fallon WM, MeltonLJ 3rd. Long-term fracture risk in patients with Crohn’s disease: A population-basedstudy in Olmsted County, Minnesota. Gastroenterology2002;123:468-75.44. Klaus J, Armbrecht, G, Steinkamp, M, Brückel J, Rieber A, Adler G, et al:Prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease.Gut 2002; 51:654-8.45. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, etal. Discordance between the degree of osteopenia and the prevalence ofspontaneous vertebral fractures in Crohn’s disease. Aliment PharmacolTher 2002; 16:1519-27.46. Xiong DH, Lei SF, Yang F, Wang L, Peng YM, Wang W et al. Low-densitylipoprotein receptor-related protein 5 (LRP5) gene polymorphims are associatedwith mass in both Chinese and whites. J Bone Miner Res 2007;22: 385-93.47. Ezura Y, Nakajima T, Urano T, Sudo Y, Kajita M, Yoshida H et al. Associationof a single-nucleotide variation (A1330V) in the low-density lipoproteinreceptor-related protein 5 gene (LRP5) with bone mineral density inadult Japanese women. Bone 2007;40:997-1005.48. Saarinen A, Valimaki VV, Valimaki MJ, Loyttyniemi E, Auro K, Uusen P etal. The A1330V polymorphism of the low-density lipoprotein receptor-relatedprotein 5 gene (LRP5) associates with low peak bone mass in younghealthy men. Bone 2007;1006-12.49. Rodriguez-Bores L, Barahona-Garrido J, Yamamoto J.K.. Basic and clinicalaspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol2007;13:6156-65.50. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1 alpha 25-DihidroxyvitaminD3 binding macromolecules in human B lymphocytes: effectson inmunoglobulin production. J Inmunol 1986;136;2734-40.51. Manolagas Sc. The role of IL-6 type cyrokines and their receptors in bone.Ann N Y Acad Sci 1998; 840:194-204.52. Montenegro Sergio D, Pedroza Nuñez I.J., Vargas Eced S. Ramos M.H.Metabolismo óseo. Actualización. Revista de Posgrado de la VIa Cátedrade Medicina. 2002;117:18-21.53. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis.Exp Gerontol 2000;35: 1047-56.54. Shoumal M, Kolarz G, Haberhauer G, Woloszcuk W, Hawa G, Kingler A.Osteoprotegerin and the receptor activator of NF-Kappa B ligand in theserum and synovial fluid. A comparison of patients with longstandingrheumatoid arthritis and osteoarthritis. Rheumatol Int 2005; 26: 63-9.55. Shoumal M, Kolarz G, Woloszcuk W, Hawa G, Kingler A. Serum Osteo-193 • Enfermedad Inflamatoria Intestinal al día - Vol. 7 - Nº. 2 - 2008